Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351183 | 0.94 | PARK7 (0.50) | PARK7EGLN1MEN1KMT2ARAB9A | |
| SCHEMBL352373 | 0.85 | EGLN1 (0.40) | PARK7EGLN1MEN1KMT2ARAB9A | |
| SCHEMBL353842 | 0.76 | PARK7 (0.50) | PARK7KMT2ARAB9APOLBMAPT | |
| SCHEMBL352796 | 0.75 | EGLN1 (0.47) | EGLN1MEN1KMT2ARAB9APOLB | |
| SCHEMBL16649916 | 0.75 | PARK7 (0.58) | PARK7MEN1KMT2ARAB9APOLB | |
| SCHEMBL351825 | 0.74 | PARK7 (0.48) | PARK7MEN1KMT2ARAB9APOLB | |
| SCHEMBL351942 | 0.73 | PARK7 (0.45) | PARK7 | |
| Trifluoroacetic Acid SCHEMBL484013 | 0.73 | PARP1 (0.50) | EGLN1MEN1KMT2APOLBHPGD | |
| SCHEMBL352312 | 0.72 | PARK7 (0.55) | PARK7EGLN1MEN1KMT2ARAB9A | |
| SCHEMBL351903 | 0.70 | PARK7 (0.45) | PARK7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | claimed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | claimed |
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | PARK7 3327/4885EGLN1 3912/4885MEN1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.